Experts debate the value of the new agent for low-grade gliomas with an IDH1 or IDH2 mutation. Some have hailed the drug a “breakthrough,” whereas others call the approval “premature.” ...

The medication is a dual inhibitor of the IDH mutation (IDH1 and IDH2). TjDr. Henry Friedman, a deputy director at the Preston Robert Tisch Brain Tumor Center at Duke University, tells SurvivorNet ...

Gliomas arise from glial cells, which protect and support a healthy nervous system. A substantial proportion of glioma cases are caused by mutations in IDH.

Shortly after the discovery of the molecular underpinnings of IDH mutations, several programs were initiated to develop drugs to inhibit the neomorphic enzymatic function of mIDH, and thus block ...

Researchers have revealed how IDH mutations in gliomas act as a "ticking time bomb," initiating slow growth before genetic mutations drive aggressive cancer progression. The study highlights ...

Patients with grade 2 astrocytoma or oligodendroglioma should be selected for treatment based on the presence of IDH1 or IDH2 mutations in tumor specimens. Voranigo ® is supplied as a tablet in 2 ...

Gliomas are the most common malignant brain tumors in adults, and mutations of the IDH genes are present in nearly all grade 2 gliomas, the researchers said in background notes.

The registration-enabling Phase III, global, randomized, double-blind placebo-controlled INDIGO study evaluated vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1/2 ...

Vorasidenib (AG-881) is promising new drug for patients with grade 2 IDH-mutant gliomas, a type of brain cancer that typically affects younger people, according to findings from the phase 3 INDIGO ...

While these cancers are rare, Servier says diffuse gliomas with IDH mutations are the most common malignant primary brain tumors diagnosed in those age 50 or younger.

Gliomas, the second-most common cancer type in Canadians under 40 years of age, spread within the brain and are not curable with current therapies. VORANIGO addresses the IDH mutation found in 60% ...